Evista: Uses, dosage, side effects, warnings & patient reviews

What is Evista (Raloxifene)?

Evista is the brand name for the drug raloxifene hydrochloride. It belongs to a class of medications known as Selective Estrogen Receptor Modulators (SERMs). SERMs work by selectively acting like the hormone estrogen in some parts of the body (such as bones) while blocking estrogen’s effects in others (such as breast tissue).

This unique mechanism makes Evista useful for two primary purposes in postmenopausal women: osteoporosis management and breast cancer risk reduction. It helps maintain bone density and strength, reducing the risk of fractures. Additionally, for women at high risk, it can significantly lower the chance of developing invasive breast cancer. It is crucial to understand that Evista is not a hormone replacement therapy (HRT) and is specifically indicated for postmenopausal women.

As a branded medication, patients should know that generic raloxifene is available. For more information on the safety and efficacy of generic options, see our guide on generic medicines.

How to Take Evista

Adhering to the correct administration guidelines is essential for Evista’s effectiveness and safety.

Administration

Take one Evista tablet by mouth once daily, with or without food. Swallow the tablet whole with a glass of water; do not crush, chew, or break it.

Since Evista is used for long-term prevention and treatment, it is important to take it consistently at around the same time each day to maintain stable drug levels in your body.

Missed Dose

If you miss a dose, take it as soon as you remember on the same day. If you do not remember until the next day, skip the missed dose and take only your regular scheduled dose. Do not take a double dose to make up for a missed one.

Duration of Therapy

Treatment with Evista is typically long-term. For osteoporosis, the benefits on bone density require continuous use. For breast cancer risk reduction, therapy is also ongoing. Do not stop taking Evista without first consulting your doctor, as the protective effects are not permanent.

Side Effects of Evista

Like all medications, Evista can cause side effects. It is helpful to understand the range of possible reactions and differentiate between common and serious ones.

What is Evista Used For?

Evista is FDA-approved for two main uses in postmenopausal women, leveraging its dual action as a SERM.

Treatment and Prevention of Osteoporosis

Evista is used both to treat and prevent osteoporosis in postmenopausal women. It helps increase bone mineral density (BMD) and reduce the risk of vertebral fractures. It is not used to treat established bone pain or to prevent fractures at other sites (like the hip) to the same extent as some other osteoporosis medications.

Reduction of Breast Cancer Risk

Evista is approved to reduce the risk of invasive breast cancer in postmenopausal women who are at high risk for the disease, as well as in those with osteoporosis. It works by blocking estrogen effects in breast tissue. It’s important to note that this is a risk-reduction use, not a treatment for existing breast cancer. For more information on breast health, visit our page on breast cancer.

Important Limitations

• Evista is only for use in postmenopausal women. Its effects and safety in premenopausal women have not been established.
• It does not treat hot flashes or other symptoms of menopause; in fact, it may cause or worsen them.
• It is not a hormone replacement therapy and does not relieve other symptoms associated with estrogen loss.

Important Safety Concerns and Considerations

Increased Risk of Blood Clots

The most significant safety concern with Evista is an increased risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). The risk is comparable to that reported with hormone replacement therapy. This risk is greatest during the first four months of treatment. Women with a history of VTE, or with active or past history of certain heart and circulatory conditions, should generally not use Evista.

Risk of Death from Stroke

A study in postmenopausal women with known coronary heart disease or at high risk for cardiovascular events found an increased risk of fatal stroke with raloxifene use. Therefore, Evista is contraindicated in women with a history of or at high risk for stroke or transient ischemic attack (TIA).

Worsening of Hot Flashes

Evista commonly causes or exacerbates hot flashes and can also cause leg cramps. These side effects are a primary reason for discontinuation of the medication and should be managed in consultation with a healthcare provider.

Use Before Surgery or Prolonged Immobility

Due to the increased risk of blood clots, women taking Evista should stop taking it at least 72 hours before planned surgery or any period of prolonged immobilization (e.g., extended bed rest during recovery). Therapy can be resumed only after the patient is fully ambulatory. It’s essential to inform your surgeon and anesthesiologist about your medication. For related information, see our guide to general anesthesia.

Critical Warnings for Evista Use

Boxed Warning: Venous Thromboembolism and Stroke

Evista carries a U.S. FDA Boxed Warning, the strongest safety alert, regarding the risks of venous thromboembolic events and fatal stroke.

• Venous Thromboembolism (VTE): Evista increases the risk of DVT and PE. The risk is similar to the reported risk associated with hormone replacement therapy. Discontinue Evista at least 72 hours prior to and during prolonged immobilization.
• Fatal Stroke: In a study of postmenopausal women with coronary heart disease or at increased risk for coronary events, Evista was associated with an increased risk of fatal stroke. It should not be used in women with a history of or at high risk for stroke.

Contraindications

Evista is contraindicated and should NOT be used in women who:

• Are or may become pregnant.
• Have a history of venous thromboembolism (blood clots in the legs, lungs, or eyes).
• Have active or past history of stroke, transient ischemic attack (TIA), or atrial fibrillation.
• Have severe liver or kidney impairment.

Inadequate Response in Breast Cancer Treatment

Evista is not indicated for the treatment of invasive breast cancer or reduction of the risk of recurrence. It is solely for risk reduction in high-risk women.

No Relief for Menopausal Symptoms

Evista does not relieve vasomotor symptoms (hot flashes) associated with menopause. In clinical trials, it was associated with an increased frequency of hot flashes.

Evista Dosage Information

The dosage of Evista is standardized, but it must be prescribed by a doctor who has evaluated your individual risk factors.

>Therapy should be continued for as long as the benefit in risk reduction is deemed appropriate by the treating physician.

Important Administration Notes

• No Dosage Adjustment: No dosage adjustment is recommended based on age or for patients with mild to moderate renal or hepatic impairment. It is not recommended for use in patients with severe impairment.
• Duration: Treatment is long-term. Benefits on bone mineral density reverse after discontinuation.
• Concomitant Use: Evista can be taken any time of the day, with or without food or other medications, except for cholestyramine (see Interactions).

Drug Interactions with Evista

Evista has a few clinically significant drug interactions. Always inform your healthcare provider about all medications you are taking.

>Concomitant use is not recommended. If must be used together, administer Evista at least 2 hours before or 4-6 hours after cholestyramine.>If starting Evista in a patient on warfarin, monitor prothrombin time more closely and adjust the warfarin dosage as necessary.>Monitor for changes in effect of either drug, though clinically significant interactions are uncommon.

Additional Information

Reporting Side Effects

You are encouraged to report negative side effects of prescription drugs to the relevant national health authority (e.g., the FDA in the United States). Reporting helps health authorities monitor drug safety and identify new risks.

Mechanism of Action (How it Works)

Raloxifene is a Selective Estrogen Receptor Modulator (SERM). It acts as an estrogen agonist (promoter) in bone, helping to maintain bone density. It acts as an estrogen antagonist (blocker) in breast tissue, which helps reduce the risk of estrogen-sensitive breast cancers. Its effects on cholesterol metabolism are complex but generally favorable.

References and Medical Sources

The information on this page is compiled from reputable medical sources and prescribing information.

1. U.S. Food and Drug Administration (FDA). Evista (raloxifene hydrochloride) Prescribing Information with Boxed Warning. [Updated 2021]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020815s034lbl.pdf
2. MedlinePlus. Raloxifene. U.S. National Library of Medicine; [Updated 2022]. https://medlineplus.gov/druginfo/meds/a699003.html
3. National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. [Updated 2023]. https://www.bonehealthandosteoporosis.org/wp-content/uploads/2016/01/995.pdf
4. Drugs.com. Raloxifene Professional Monograph. Drugs.com; [Updated 2024]. https://www.drugs.com/monograph/raloxifene.html

Disclaimer: The information on this site is provided for informational purposes only and is not medical advice. It does not replace professional medical consultation, diagnosis, or treatment. Do not self-medicate based on the information presented on this site. Always consult with a doctor or other qualified healthcare professional before making any decisions about your health.